We reviewed the impact of ivacaftor on Scottish paediatric patients with cystic fibrosis ≥6 years of age after 12 months of treatment. Statistically significant improvements in FEV 1 and body mass index and a reduction in sweat chloride, all comparable with previously published data were observed. The findings also suggested reduced use of intravenous antibiotics and oral antibiotics. No significant adverse effects were observed but a possible association with cataract formation could not be excluded. This review suggests that, in the short term at least, ivacaftor is effective and safe in paediatric patients ≥6 years of age with G551D.
BACKGROUND
The cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, ivacaftor, was granted a European licence in July 2012 and became available to Scottish patients with cystic fibrosis (CF) aged ≥6 years with the G551D mutation in early 2013. Efficacy and safety data had come from two, manufacturer-sponsored, randomised controlled trials 1 2 with small patient numbers; 26 children aged 6-11 years and 19 young people aged 12-17 years received the drug.
As a new drug with a novel mode of action, it is important to monitor the outcomes of ivacaftor administration in children with CF post-marketing. In Scotland, there is a high prevalence of the G551D mutation (11.19% compared with 5.7% in the UK, data from CF Registry report 2014) and an established managed clinical network (Scottish Paediatric Cystic Fibrosis Managed Clinical Network (SPCFMCN)) that reduces clinical management variability through the development of agreed standards of care. These factors make Scotland particularly suitable for a review of reallife outcomes.
METHODS
Retrospective data on FEV 1 , weight, height, sweat chloride, antibiotic courses and adverse effects were collected from all Scottish clinics delivering paediatric CF care using a standard form. Data were anonymised and entered into an Excel spreadsheet for analysis. Per cent predicted FEV 1 was calculated using Global Lung Initiative (GLI) references. SD (Z) scores were calculated for weight, height and body mass index (BMI) to adjust for normal growth by age and gender. The paired t test was used to evaluate changes in mean values from baseline. Ethics approval was not necessary in accordance with guidance issued by the National Health Service (NHS) Research Ethics Service.
RESULTS
One hundred per cent of data collection forms were returned. Twenty-seven children attending 11 clinics were identified. One patient was excluded from analysis because he was wholly non-compliant with treatment. He was a 15-year-old boy with a background of mental health problems which impacted on his acceptance of all prescribed medications; there were no concerns about adverse effects. Of the remaining 26 children audited, 22 started treatment between January and March 2013, one started earlier on compassionate grounds and three started later upon reaching their sixth birthday. The children had been on ivacaftor an average of 17.0 months (range 12-22) when their data were submitted and commenced treatment at a median age of 9.3 years (range 6.0-14.6). There was a female preponderance (69%). All children had at least one copy of the G551D mutation. The second gene was dF508 in 73%. One child was homozygous for G551D. One child was chronically and two intermittently infected with Pseudomonas aeruginosa at baseline. Ninety-two
What is already known on this topic?
▸ Ivacaftor is a new drug with a novel mode of action. ▸ It is licensed for patients with cystic fibrosis (CF) with specific genotypes. ▸ Manufacturer-sponsored randomised controlled trials suggest a mean increase in FEV 1 of 10.1-10.7%.
What this study adds?
▸ In a 'real-life' setting, we observed a mean increase in FEV 1 of 7.1% at 1 year. ▸ In the short term at least, ivacaftor appears to be safe and effective in Scottish paediatric patients with CF ≥6 years of age with the G551D mutation. per cent of patients were pancreatic insufficient. Two children (8%) had a diagnosis of CF liver disease as defined by best practice guidance. 3 None of the children had CF-related diabetes. Three children (12%) were on nutritional supplements. Five (19%) were on regular intravenous antibiotics (given at set intervals as part of care package at discretion of responsible clinician). Two children (8%) had type I diabetes mellitus, one of whom also had hypothyroidism. There were no other significant comorbidities.
The pretreatment and post-treatment results for FEV 1 , growth parameters and sweat chloride compared with published data are displayed in table 1.
Three children were overweight at baseline and remained so. Three, who were of healthy weight at baseline, became overweight (as defined by the International Obesity Task Force).
Eighteen children had sweat chloride measured at baseline and on treatment. It remained >60 mmol/L (diagnostic range for CF) in five children (28%). Mean increases in FEV 1 and BMI within this group were 4.2% and 1.52 kg/m 2 , respectively. The G551D homozygote was a 6-year-old boy with an FEV 1 of 98.1% predicted and a BMI of 15.7 kg/m 2 at baseline. These parameters were essentially unchanged after 1 year of treatment; however, sweat chloride fell from 106 mmol/L to 13 mmol/L, which was the lowest measurement in the whole group.
Other clinically significant findings were: of the five children receiving regular intravenous antibiotics at baseline, one child was able to stop and two had the frequency reduced; seven (27%) required fewer courses of oral antibiotics for mild respiratory exacerbations and seven (27%) were able to reduce their dose of pancreatic enzyme replacement therapy (PERT), a change that was overseen by a dietitian in all cases.
Possible adverse effects reported included transient headaches (n=1), transient unilateral ear swelling (n=1) and non-visually significant cataracts with no clear cause, detected 2-3 months into treatment with ivacaftor in two out of the 12 patients who had ophthalmological screening examinations. Liver function tests were monitored regularly by all clinics with no clinically significant derangements observed.
DISCUSSION
The findings of this review of a Scottish paediatric population, in keeping with published data, show statistically significant improvements in FEV 1 and BMI and a reduction in sweat chloride after 12 months of treatment with ivacaftor. Similarly, there were observed reductions in the number of courses of antibiotic therapy and PERT dose.
The mean absolute increase in FEV 1 of 7.1% was lower than that reported in the randomised phase III trials (10.7% for 6-11-year-olds 1 and 11.4% for 12-17-year-olds 2 ) and patients aged ≥6 years real-world outcomes being studied at Cork University Hospital 4 (10.26%), but similar to the post-approval evaluation of ivacaftor published by Rowe et al 5 (6.7%). It is, perhaps, not surprising that our 'real-life' data are slightly less compelling than data gained from tightly controlled clinical trials. Factors that could contribute to the difference include reduced patient adherence to treatment, no exclusion criteria (inhaled hypertonic saline was not discontinued, one child had low baseline FEV 1 of 30% and one had high baseline FEV 1 >105%) and the use of different lung function reference equations for calculating per cent predicted values. We used GLI references, whereas the phase III trials used Knudson and Rowe et al used Wang.
The increase in weight and BMI observed in our population was similar to that reported by Davies et al 1 and one might BMI Mean (kg/m2) Range expect Rowe's cohort to be similar at 1 year considering their 6-month data. 5 Three children in our group became overweight over the course of their year on ivacaftor. The adverse effects of being overweight/obese on long-term general health for patients with CF are now becoming topical. The nutritional status of patients on ivacaftor will need to be monitored closely and dietetic advice tailored accordingly. Information from the All Wales Adult CF Centre 6 is reassuring and indicates that increase in weight is mainly fat-free mass, but there are no comparative data for children and fat-free mass data were not collected in this review.
No significant adverse effects were noted. The association of cataract formation and ivacaftor in animal models led five of the 11 Scottish clinics to perform eye screening during the review. It is unknown whether the two children with non-visually significant cataracts had them before or developed them during treatment. A formal recommendation to carry out baseline and follow-up ophthalmological examinations for all paediatric patients initiating treatment with ivacaftor has now been added to the Summary of Product Characteristics by the manufacturer.
In conclusion, this review suggests that in the short term at least, ivacaftor is effective and safe in paediatric patients with CF ≥6 years of age with G551D in Scotland. Continued monitoring is required to inform on long-term efficacy and safety.
